SATELLOS Announces the Appointment of Philip D. Lambert, Ph.D, as Chief Technology Officer
Satellos Bioscience Inc. Announces the Appointment of Philip D. Lambert, Ph.D, as Chief Technology Officer
SATELLOS Announces Closing of Offering of Units
NOT FOR RELEASE OR DISTRIBUTION IN THE UNITED STATES OR FOR DISSEMINATION TO U.S. NEWS
SATELLOS Announces the Filing of Final Short Form Prospectus for Proposed Offering of Units
NOT FOR RELEASE OR DISTRIBUTION IN THE UNITED STATES OR FOR DISSEMINATION TO U.S. NEWS
SATELLOS Announces Pricing of Proposed Offering of Units
NOT FOR RELEASE OR DISTRIBUTION IN THE UNITED STATES OR FOR DISSEMINATION TO U.S. NEWS
SATELLOS Reports Q2 2022 Financials and Operating Results
NOT FOR RELEASE OR DISTRIBUTION IN THE UNITED STATES OR FOR DISSEMINATION TO U.S. NEWS
SATELLOS Announces the Filing of an Amended and Restated Preliminary Prospectus for Proposed Offering of Units
NOT FOR RELEASE OR DISTRIBUTION IN THE UNITED STATES OR FOR DISSEMINATION TO U.S. NEWS
SATELLOS Co-Founder and Chief Scientific Officer Dr. Michael Rudnicki Published in Nature Communications
TORONTO, July 13, 2022 – Satellos Bioscience Inc. (TSXV: MSCL) (“Satellos” or the “Corporation”), a
SATELLOS Announces Proposed Offering of Units
NOT FOR RELEASE OR DISTRIBUTION IN THE UNITED STATES OR FOR DISSEMINATION TO U.S. NEWS
SATELLOS Announces In-Licensing of New Patent Application
TORONTO, June 30, 2022 – Satellos Bioscience Inc. (TSXV: MSCL) (“Satellos” or the “Company”), a
SATELLOS Co-Founder and Chief Scientific Officer Dr. Michael Rudnicki Officially Recognized as a Fellow of the Royal Society
TORONTO, June 22, 2022 – Satellos Bioscience Inc. (TSXV: MSCL) (“Satellos” or the “Corporation”), a